SuperworthAVITA Medical price to book ratio RCEL
Market value divided by the book value of the company's net assets, since 2020.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 54.1×
- May 2025
- 6-year median
- 5.1×
- 6-year range
- 1.2× to 61.9×
- Peer median
- 3.1×
AVITA Medical's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.
It was last meaningful in May 2025, at 54.1×.
On the days it had one over the last 6 years, its median was 5.1×, from 1.2× in Jun 2022 to 61.9× in Feb 2025.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 54.1× | 18.5× | 61.9× |
| 2024 | 28.9× | 4.3× | 28.9× |
| 2023 | 5.6× | 2.0× | 6.8× |
| 2022 | 1.9× | 1.2× | 2.5× |
| 2021 | 2.7× | 2.7× | 9.3× |
| 2020 | 6.1× | 5.8× | 8.5× |
Against its peers
Companies in Medical - Instruments & Supplies nearest AVITA Medical's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| RCELAVITA Medical | n/m |
| TCMDTactile Systems Technology | 2.4× |
| MDXGMimedx | 2.6× |
| EMBCEmbecta | n/m |
| MOVMovado | 1.4× |
| INFUInfuSystem | 4.7× |
| UTMDUtah Medical Products | 1.9× |
| IRMDIradimed | 10.8× |
| STAAStaar Surgical | 3.1× |
| PDEXPro DEX | 4.2× |
| BVSBioventus | 5.5× |
| Peer median | 3.1× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on AVITA Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.